Zacharioudakis Ioannis M, Zervou Fainareti N, Ziakas Panayiotis D, Mylonakis Eleftherios
Infectious Diseases Division, Rhode Island Hospital, Providence, Rhode Island; and Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Infectious Diseases Division, Rhode Island Hospital, Providence, Rhode Island; and Warren Alpert Medical School of Brown University, Providence, Rhode Island
J Am Soc Nephrol. 2014 Sep;25(9):2131-41. doi: 10.1681/ASN.2013091028. Epub 2014 Mar 20.
Patients undergoing dialysis are particularly vulnerable to methicillin-resistant Staphylococcus aureus (MRSA) infections. We performed a meta-analysis of published studies to estimate the prevalence of MRSA colonization in dialysis patients, time trends, and long-term risk of subsequent MRSA infections. Our search of the PubMed and Embase databases returned 5743 nonduplicate citations, from which we identified 38 relevant studies that included data on 5596 dialysis patients. The estimated prevalence of MRSA colonization was 6.2% (95% confidence interval [95% CI], 4.2% to 8.5%). The prevalence increased over time but remained stable after 2000. Stratification of patients according to dialysis modality and setting revealed that 7.2% (95% CI, 4.9% to 9.9%) of patients on hemodialysis were colonized with MRSA compared with 1.3% (95% CI, 0.5% to 2.4%) of patients on peritoneal dialysis (P=0.01), and that a statistically significant difference existed in the percentage of colonized inpatients and outpatients (14.2% [95% CI, 8.0% to 21.8%] versus 5.4% [95% CI, 3.5% to 7.7%], respectively; P=0.04). Notably, the risk of developing MRSA infections increased among colonized hemodialysis patients compared with noncolonized patients (relative risk, 11.5 [95% CI, 4.7 to 28.0]). The long-term (6-20 months) probability of developing a MRSA infection was 19% among colonized hemodialysis patients compared with only 2% among noncolonized patients. In summary, 6.2% of dialysis patients are MRSA colonized, and the average prevalence of colonization has remained stable since 2000. Colonization in hemodialysis patients is associated with increased risk of MRSA infection.
接受透析治疗的患者特别容易感染耐甲氧西林金黄色葡萄球菌(MRSA)。我们对已发表的研究进行了荟萃分析,以估计透析患者中MRSA定植的患病率、时间趋势以及后续发生MRSA感染的长期风险。我们在PubMed和Embase数据库中检索,共获得5743条不重复的文献引用,从中识别出38项相关研究,这些研究包含了5596例透析患者的数据。MRSA定植的估计患病率为6.2%(95%置信区间[95%CI],4.2%至8.5%)。患病率随时间增加,但在2000年后保持稳定。根据透析方式和环境对患者进行分层分析显示,血液透析患者中7.2%(95%CI,4.9%至9.9%)被MRSA定植,而腹膜透析患者中这一比例为1.3%(95%CI,0.5%至2.4%)(P = 0.01),并且住院患者和门诊患者的定植百分比存在统计学显著差异(分别为14.2%[95%CI,8.0%至21.8%]和5.4%[95%CI,3.5%至7.7%];P = 0.04)。值得注意的是,与未定植的患者相比,定植的血液透析患者发生MRSA感染的风险增加(相对风险,11.5[95%CI,4.7至28.0])。在定植的血液透析患者中,发生MRSA感染的长期(6 - 20个月)概率为19%,而未定植患者中仅为2%。总之,6.2%的透析患者被MRSA定植,自2000年以来定植的平均患病率保持稳定。血液透析患者的定植与MRSA感染风险增加相关。